Top in ID: COVID-19 ‘long haulers,’ vaccine efficacy in older adults
Nonhospitalized COVID-19 survivors had a nearly 60% increased risk for death after the first 30 days of illness, according to a recent study. It was the top story in infectious disease last week.
Another study investigated the efficacy of mRNA COVID-19 vaccines in a real-world setting. The data revealed that the Pfizer-BioNTech and Moderna vaccines were 94% effective against COVID-19 hospitalization among fully vaccinated older adults and 64% effective among partially vaccinated older adults. This was another top story.
Read these and more news in infectious disease below:
COVID-19 ‘long haulers’ face ‘substantial burden of health loss’
Patients more than 30 days out from a COVID-19 diagnosis experience an excess burden of a variety of health conditions, and even patients with mild cases face an increased risk for death in the ensuing 6 months, researchers reported. Read more.
Real-word study shows vaccines protect against COVID-19 hospitalization in older adults
Data from a small real-world study demonstrated that receiving two doses of the Pfizer-BioNTech or Moderna COVID-19 vaccine is 94% effective against COVID-19 hospitalization among adults aged 65 years or older, researchers reported in MMWR. Read more.
CDC: Fully vaccinated people do not need masks outdoors, except in crowds
Fully vaccinated people do not need to wear masks outdoors “except in certain crowded settings and venues,” the CDC said in updated guidance. Read more.
As CDC, FDA lift pause of J&J vaccine, poll indicates ‘eroded confidence’ in shot
The CDC and FDA lifted a recommended pause on the Johnson & Johnson COVID-19 vaccine rollout in the United States after a panel of experts encouraged its use despite a small number of clotting events linked to the shot. Read more.
US pledges help for coronavirus-stricken India
As the COVID-19 situation in India continues to grow more dire, countries around the world are pledging help — including the United States, which has promised to send raw materials required to make coronavirus vaccines and other supplies. Read more.